{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"127"},{"groupId":"OG001","spread":"29.1","value":"119"},{"groupId":"OG002","spread":"24.5","value":"127"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Cmax: DS-8201a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.1","value":"137"},{"groupId":"OG001","spread":"25.6","value":"128"},{"groupId":"OG002","spread":"23.2","value":"123"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cmax: DS-8201a, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.6","value":"116"},{"groupId":"OG001","spread":"26.1","value":"105"},{"groupId":"OG002","spread":"19.6","value":"110"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Cmax: Total Anti-HER2 antibody, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.4","value":"121"},{"groupId":"OG001","spread":"24.2","value":"115"},{"groupId":"OG002","spread":"21.9","value":"112"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cmax: Total Anti-HER2 antibody, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.08","value":"5.56"},{"groupId":"OG001","spread":"2.42","value":"4.52"},{"groupId":"OG002","spread":"23.4","value":"9.51"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Ctrough: DS-8201a, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.3","value":"13.4"},{"groupId":"OG001","spread":"3.09","value":"8.84"},{"groupId":"OG002","spread":"18.6","value":"13.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Ctrough: DS-8201a, Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.60","value":"8.56"},{"groupId":"OG001","spread":"2.97","value":"5.33"},{"groupId":"OG002","spread":"20.5","value":"10.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Ctrough: Total Anti-HER2 antibody, Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.6","value":"15.6"},{"groupId":"OG001","spread":"5.76","value":"12.2"},{"groupId":"OG002","spread":"17.6","value":"14.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Ctrough: Total Anti-HER2 antibody, Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for DS-8201a and total anti-HER2 antibody were estimated in each participant using standard noncompartmental methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG001","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG002","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","timeFrame":"Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)","title":"Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of DS-8201a and Total Anti-HER2 Antibody Following Treatment With DS-8201a","type":"SECONDARY","unitOfMeasure":"ug/mL"}